BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma

被引:29
作者
Busacca, Sara
Sheaff, Michael [2 ]
Arthur, Kenneth [1 ]
Gray, Steven G. [3 ]
O'Byrne, Kenneth J. [3 ]
Richard, Derek J. [4 ]
Soltermann, Alex [5 ]
Opitz, Isabelle [6 ]
Pass, Harvey [7 ]
Harkin, D. Paul
Quinn, Jennifer E. [1 ]
Fennell, Dean A. [1 ]
机构
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Tissue Core Technol Unit, Belfast BT9 7BL, Antrim, North Ireland
[2] Barts & London NHS Trust, Dept Cellular Pathol, London, England
[3] St James Hosp, Dept Cardiothorac Surg, Dublin, Ireland
[4] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[5] Univ Zurich Hosp, Inst Clin Pathol, Zurich, Switzerland
[6] Univ Zurich Hosp, Div Thorac Surg, Zurich, Switzerland
[7] New York Med Ctr, Dept Cardiothorac Surg, New York, NY USA
关键词
malignant pleural mesothelioma; vinorelbine; BRCA1; resistance; MALIGNANT-PLEURAL-MESOTHELIOMA; CELL LUNG-CANCER; RNA EXPRESSION LEVELS; PROTEIN EXPRESSION; SPORADIC OVARIAN; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY; INHIBITION; CARCINOMAS;
D O I
10.1002/path.3979
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Therapeutic options for malignant pleural mesothelioma (MPM) are limited despite the increasing incidence globally. The vinca alkaloid vinorelbine exhibits clinical activity; however, to date, treatment optimization has not been achieved using biomarkers. BRCA1 regulates sensitivity to microtubule poisons; however, its role in regulating vinorelbine-induced apoptosis in mesothelioma is unknown. Here we demonstrate that BRCA1 plays an essential role in mediating vinorelbine-induced apoptosis, as evidenced by (1) the strong correlation between vinorelbine sensitivity and BRCA1 expression level; (2) induction of resistance to vinorelbine by BRCA1 using siRNA oligonucleotides; (3) dramatic down-regulation of BRCA1 following selection for vinorelbine resistance; and (4) the re-activation of vinorelbine-induced apoptosis following re-expression of BRCA1 in resistant cells. To determine whether loss of BRCA1 expression in mesothelioma was potentially relevant in vivo, BRCA1 immunohistochemistry was subsequently performed on 144 primary mesothelioma specimens. Loss of BRCA1 protein expression was identified in 38.9% of samples. Together, these data suggest that BRCA1 plays a critical role in mediating apoptosis by vinorelbine in mesothelioma, warranting its clinical evaluation as a predictive biomarker. Copyright (c) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:200 / 208
页数:9
相关论文
共 32 条
[1]
ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer [J].
Bessho, Yuji ;
Oguri, Tetsuya ;
Ozasa, Hiroaki ;
Uemura, Takehiro ;
Sakamoto, Hideo ;
Miyazaki, Mikinori ;
Maeno, Ken ;
Sato, Shigeki ;
Ueda, Ryuzo .
ONCOLOGY REPORTS, 2009, 21 (01) :263-268
[2]
Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients [J].
Boukovinas, Ioannis ;
Papadaki, Chara ;
Mendez, Pedro ;
Taron, Miquel ;
Mavroudis, Dimitris ;
Koutsopoulos, Anastasios ;
Sanchez-Ronco, Maria ;
Javier Sanchez, Jose ;
Trypaki, Maria ;
Staphopoulos, Eustathios ;
Georgoulias, Vassilis ;
Rosell, Rafael ;
Souglakos, John .
PLOS ONE, 2008, 3 (11)
[3]
Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent [J].
Chao, Suzan K. ;
Lin, Juan ;
Brouwer-Visser, Jurriaan ;
Smith, Amos B., III ;
Horwitz, Susan Band ;
McDaid, Hayley M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (01) :391-396
[4]
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 [J].
Drew, Yvette ;
Mulligan, Evan A. ;
Vong, Wan-Tse ;
Thomas, Huw D. ;
Kahn, Samra ;
Kyle, Suzanne ;
Mukhopadhyay, Asima ;
Los, Gerrit ;
Hostomsky, Zdenek ;
Plummer, Elizabeth R. ;
Edmondson, Richard J. ;
Curtin, Nicola J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (04) :334-346
[5]
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[6]
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development [J].
Fennell, DA ;
Rudd, RM .
LANCET ONCOLOGY, 2004, 5 (06) :354-362
[7]
Advances in the systemic therapy of malignant pleural mesothelioma [J].
Fennell, Dean A. ;
Gaudino, Giovanni ;
O'Byrne, Kenneth J. ;
Mutti, Luciano ;
van Meerbeeck, Jan .
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (03) :136-147
[8]
Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer [J].
Fiorentino, Michelangelo ;
Judson, Gregory ;
Penney, Kathryn ;
Flavin, Richard ;
Stark, Jennifer ;
Fiore, Christopher ;
Fall, Katja ;
Martin, Neil ;
Ma, Jing ;
Sinnott, Jennifer ;
Giovannucci, Edward ;
Stampfer, Meir ;
Sesso, Howard D. ;
Kantoff, Philip W. ;
Finn, Stephen ;
Loda, Massimo ;
Mucci, Lorelei .
CANCER RESEARCH, 2010, 70 (08) :3136-3139
[9]
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[10]
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway [J].
Lafarge, S ;
Sylvain, V ;
Ferrara, M ;
Bignon, YJ .
ONCOGENE, 2001, 20 (45) :6597-6606